NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









RxAnte

RxAnte

Private
Portland, MaineHealthcare & Life Scienceshttps://www.rxante.com/

Last Round

Private Equity

Jan 12, 2026

Total Funding Raised

$19.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

RxAnte is a healthcare technology systems company that provides predictive analytics and targeted clinical programs intended to improve medication prescribing and adherence.

Sector

Healthcare & Life Sciences

Verticals

Healthcare Analytics, Vertical SaaS, Patient Engagement, Medical AI, Workflow Automation

Business Model

B2B

Customer Profile

Services & Consulting, Subscription SaaS

AI Layer

Application

Keywords

medication adherencepharmacy care managementpredictive analyticsvalue-based pharmacymedication therapy managementMedicare Star Ratingsvalue-based carepharmacy analyticshealth plan solutionscomplex patient managementHEDISadherence packagingrisk-based contractsaccountable care organizationsACOMedicare AdvantageHITRUST certified

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

RxAnte Comparables

Compare RxAnte with similar companies based on industry and business-model similarity.

RxAnte comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AdhereHealth
91%
Arine
82%
AssistRx
78%

RxAnte Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Private EquityJan 12, 2026
DebtDec 20, 2022
Growth EquityOct 5, 2016
Series ASep 1, 2012

Key People

Founding team and executive leadership

Josh Benner

Chief Executive Officer

Executive Team

RxAnte Investors

Notable investors and investment history

RxAnte investors
InvestorRounds
PNC Erieview CapitalPrivate Equity
Primus Capital PartnersPrivate Equity
Aberdare VenturesSeries A
Trinity CapitalDebt
UPMC EnterprisesPrivate Equity, Growth Equity

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 12, 2026

    Primus Capital Partners led the round with UPMC Enterprises and PNC Erieview Capital also participating.

  • May 1, 2025

    Monthly visitors grew 166% MoM, reaching 33K.

RxAnte Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

RxAnte Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about RxAnte's valuation, stock price, and market status.

Firmographic Details

HeadquartersPortland, Maine
Employee Range92
Year Founded2011
Last FundingJan 12, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.